Releasing the restraints of VÎ³9VÎ´2 T-cells in cancer immunotherapy.

Ridgley, Laura A; Caron, Jonathan; Dalgleish, Angus; Bodman-Smith, Mark

Ridgley, Laura A; Caron, Jonathan; Dalgleish, Angus; Bodman-Smith, Mark.

Afiliación

Ridgley LA; Institute for Infection and Immunity, St. George's University of London, London, United Kingdom.
Caron J; Institute for Infection and Immunity, St. George's University of London, London, United Kingdom.
Dalgleish A; Institute for Infection and Immunity, St. George's University of London, London, United Kingdom.
Bodman-Smith M; Institute for Infection and Immunity, St. George's University of London, London, United Kingdom.

Front Immunol ; 13: 1065495, 2022.

Article en En | MEDLINE | ID: mdl-36713444

Asunto(s)

Neoplasias; Linfocitos T; Humanos; Inhibidores de Puntos de Control Inmunológico/metabolismo; Receptores de Antígenos de Linfocitos T gamma-delta/metabolismo; Activación de Linfocitos; Inmunoterapia; Neoplasias/terapia; Neoplasias/metabolismo

Palabras clave

BCG; NKG2A; VÎ³9VÎ´2 T-cell; ZA; immune checkpoint inhibitor

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos T / Neoplasias Límite: Humans Idioma: En Revista: Front Immunol Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google